Latest KFF Health News Stories
Behind The EpiPen Monopoly: Lobbying Muscle, Flailing Competition, Tragic Deaths
A closer look shows that industry lobbying was just one factor in EpiPen’s sales explosion.
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
‘America’s Other Drug Problem’: Copious Prescriptions For Hospitalized Elderly
Older people are often given a huge number of medications, and many of them are unnecessary or even harmful.
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
Insurance Rules Can Hamper Recovery From Opioid Addiction
Medicaid and other health insurers require doctors to file time-consuming paperwork before allowing them to prescribe drugs that help people quit opioids. That delay fosters relapse, specialists say.
Syncing Up Drug Refills: A Way To Get Patients To Take Their Medicine
A study published in Health Affairs concludes that the idea of coordinating prescription refill timelines for people with multiple chronic conditions could improve their medication adherence and health outcomes.
Teaching Future Doctors About Addiction
Most medical schools offer very little education on treating opioid addiction. Stanford University’s medical school is trying to ramp it up.
Study Bodes Well For Biosimilars But Highlights Need For More Research
Some experts said the findings stemming from this systematic review of existing studies was reassuring, but not surprising.
Opioid Dependence Leads To ‘Tsunami’ Of Medical Services, Study Finds
Insurance claims for medical services related to opioid dependence diagnoses rose more than 3,000 percent between 2007 and 2014, an analysis finds.
Study: Medicare Beneficiaries May Face ‘Treatment Gap’ For Painkiller Abuse, Misuse
The incidence of opioid use disorder is growing rapidly within the Medicare population.
Fraud Concerns Emerge As Compounding Drug Sales Skyrocket
Federal spending has soared for drugs that are handmade in local pharmacies, and federal investigators are raising concerns about fraud or overbilling.
Despite Opioid Concerns, Seniors Often Exit The Hospital With Prescription: Study
Researchers found that nearly 15 percent of seniors filled prescriptions for an opioid painkiller after leaving the hospital and of those, 42.5 percent had the order refilled later.
Heart Failure Patients Warned About The Dangers Of Mixing Prescriptions
The American Heart Association issues a statement to guide heart failure patients and doctors about the effects that drugs for other conditions can have on the heart.
Sounds Like A Good Idea? Regulating Drug Prices
Presidential candidates from both parties have proposals they say would help lower the cost of prescription drugs. But most experts say that efforts to regulate prices might not end up saving much money.
Gingrich, Kennedy Take On Opioid Addiction — The KHN Conversation
Patrick Kennedy, a former congressman from Rhode Island, and Newt Gingrich, who was once the House speaker, are advancing policies to combat this national crisis.
Medical Marijuana Linked To Modest Budget Benefits For Medicare Part D, Study Finds
A Health Affairs study determines that Part D spending went down slightly on prescription drugs for which medical marijuana is viewed as a possible alternative.
Study: Brand-Name Drugs’ High Copays Soak Medicare Part D Patients
A study in Health Affairs finds Medicare Part D beneficiaries were charged copays averaging 10.5 times more for Crestor and Nexium than generic drugs would have cost them.
Medicaid, Private Insurers Begin To Lift Curbs On Pricey Hepatitis C Drugs
Over the past few months, Massachusetts, Florida, New York, Delaware and Washington have lifted restrictions on the expensive medications, and private insurers around the country are also making the changes.
